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Background:  Spexin (SPX) is a recently discovered neuropeptide that exhibits a 
large spectrum of central and peripheral regulatory activity, especially when 
considered as a potent anorexigenic factor. It has already been proven that 
antidepressants, including selective serotonin reuptake inhibitors (SSRI), can 
modulate peptidergic signaling in various brain structures. Despite these findings, 
there is so far no information regarding the influence of treatment with the SSRI 
antidepressant escitalopram on brain SPX expression.  
 
Methods: In this current study we measured SPX mRNA and protein expression in 
the selected brain structures (hypothalamus, hippocampus and striatum) of rats 
chronically treated with  a 10mg/kg dose of escitalopram using quantitative Real-
Time PCR and immunohistochemistry.  
 
Results: Strikingly, long-term (4 week) drug treatment led to the downregulation of 
SPX expression in the rat hypothalamus. This supports the hypothesis that SPX may 
be involved in the hypothalamic serotonin-dependent actions of SSRI 
antidepressants and possibly also in the central mechanism of body mass increase. 
Conversely, SPX expression increased in the hippocampus and striatum. 
  
Conclusions: This is the first report of the effects of a neuropsychiatric medication 
on SPX expression in animal brain. Our findings shed a new light on the 
pharmacology of antidepressants and may contribute to a better understanding of 
the alternative mechanisms responsible for antidepressant action. 
 
 










Neuropeptides regulate a wide pool of diverse brain functions. Biochemical 
and molecular analysis of cellular interplay within brain centres has recently 
improved together with precise description of local neuronal networks. This coupled 
with  the novel discoveries of new multifunctional neuropeptides such as nesfatin-1 
and phoenixin [1-3] has led to a new era of understanding of neuropeptide-brain 
interactions.  
Spexin (SPX) is one such intriguing novel neuropeptide, a product of the 
Ch12orf39 gene which was found thanks to advanced bioinformatics methods [4]. 
The function of this regulatory factor is currently under examination with SPX 
demonstrating no molecular structure similarities  to known neuropeptides. Rat SPX 
differs from the human and mouse molecules by only one amino acid at the C-
terminal domain [5]. In the brain, many SPX immunopositive neural populations have 
been described, while neuroglia are usually negative, the highest reaction was 
detected in the hypothalamic paraventricular and supraoptic nuclei. Hippocampal 
neurons show moderate immunoreactivity as well as cerebellar Purkinje cells and 
brainstem neurons [6].  
SPX seems to have multiple physiological functions with studies in goldfish 
revealing the involvement of SPX in reproduction and food-intake regulation. 
Treatment of animals with SPX decreased the secretion of luteinizing hormone  and 
also suppressed appetite.  Brain injection of goldfish with SPX inhibited both basal 
and NPY- or orexin-dependent consumatory behaviour and food intake [7]. Similarly, 
a new finding also reports, that in another fish; orange-spotted grouper (Epinephelus 
coioides) central SPX administration decreased orexin but increased POMC mRNA 
expression in the hypothalamus [8]. Intriguing recent results published by Walewski 
et al. [9] showed that  SPX may be a strongly anorexigenic factor involved in weight 
regulation, with novel potential for obesity therapy. SPX may also be a fat-expressed 
satiety factor [10]. Recent findings also demonstrates a role for SPX in the control of 
cardiovascular/renal function and nociception [5,11]. Intracerebroventricular SPX 
injection decreased the heart rate of rats without modulation of the blood pressure, 
but with a high elevation  of urine production [11]. It also reported that SPX 
stimulated basal aldosterone secretion from freshly isolated adrenal endocrine cells. 
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Extended exposure of this culture to SPX resulted in a limited increase in 
corticosterone secretion and a significant decrease of cell proliferation [12]. In terms 
of mechanistic function, a ligand-receptor interaction study suggested that SPX may 
be a natural ligand for the GALR2/3 receptors. Moreover, SPX exhibits even higher 
potency toward GALR3 than galanin [13]. Interestingly an artificial SPX-based 
human GALR2 receptor agonist exerts an anxiolytic effect in mice [14]. On the other 
hand, SPX does stimulate intestinal peristaltic movement through GALR2-dependent 
activation of  L-type calcium VDCC channels in the murine smooth muscle cells [15]. 
Escitalopram is an S-enantiomer of citalopram, a well-known highly selective 
serotonin reuptake inhibitor (SSRI) and a very effective treatment for depression and 
anxiety disorders. It has more potent allosteric affinity to the neuronal serotonin 
transporter (SERT) molecule than pure R-enantiomer or even isomer mixtures and 
therefore its pharmacological effect is especially beneficial with a satisfactory 
tolerance profile [16]. Escitalopram does not bind to serotonin, dopamine (D1 and 
D2), muscarinic and histamine receptors, which minimize the range of its potential 
side effects. SSRI-related changes in energy homeostasis and weight gain are often 
clinically observed [17,18], however little is known about peptidergic neuronal 
pathways which could be additional targets for these medications. Serotonin neurons 
located in the midline raphe nuclei send numerous long afferents to almost all brain 
structures including the hypothalamus, thalamus, hippocampus and neocortex.  
There are many suggestions that SSRI treatment may affect the hypothalamic 
corticotropin-releasing factor (CRF) pathway [19,20] and hypothalamo-pituitary 
adrenal (HPA) axis [21]. Interestingly, 2 hours after escitalopram administration the 
level of TRH-like peptides was increased in the rat nucleus accumbens, striatum, 
cerebellum and medulla oblongata, while TRH concentration was decreased in the 
nucleus accumbens. It should not be therefore excluded that SSRI action is 
mediated by modulation of TRH and TRH-like neuropeptides [22]. Potential direct or 
indirect action of SSRIs at the level of brain spexin signalling are so far completely 
unknown.  
The present experimental paradigm aims to shed light on this area by 
determining  if and how long-term treatment with escitalopram influences the 
expression of spexin in the rat brain.  In the current study we evaluated for the first 
time the level of SPX mRNA and protein in the selected brain structures; 
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hippocampus, hypothalamus and striatum after drug administration. The results 
cautiously indicate that extended escitalopram administration may significantly 
modulate spexin regulatory activity.  
 




The studies were carried out on adult (2-3 months old, 185-220 g) male 
Sprague-Dawley rats housed at 220C with a regular 12/12 light-dark cycle with 
access to standard Murigran chow and water ad libitum. All experimental procedures 
were approved by the local bioethic committee (agreement no 36/2012).  
 
Drug administration and tissue collection 
 
Two groups of rats (n=4) received intraperitoneal injections with respectively 
physiological saline and escitalopram at dose 10mg/kg/day every day for 4 weeks 
(28 injections). The dose used at the experiment were taken from the publications 
where authors examine the influence of the escitalopram on the neuropeptide 
expression in  the rat brain [19, 23]. 24 hours after the last drug administration, 
animals were anaesthetized with isoflurane and quickly sacrificed. Samples of 
hypothalamus, hippocampus and  striatum were microsurgically excised from the 
brain halves for RNA isolation. Remaining tissues were ﬁxed (with 4% 
paraformaldehyde in PBS, pH 7.2–7.4) for immunohistochemistry.  
 
Real Time-PCR reaction 
 
 Total mRNA was extracted from the collected brain tissues via 
homogenization with an ultrasound homogenizer (Heildoph DIAX 900,Germany) in 1 
ml of TRIzol® Reagent (Life Technologies). mRNA isolation was performed 
according to Chomczynski and Sacchi (1987) using chlorophorm/isopropanol and 
75% ethanol with samples finally dissolved in 50 μl of RNAse-free water. Collected 
mRNA samples were transcribed into cDNA during incubation in buffered solution of 
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reverse transcriptase MMLV-RT with RNAsin, oligo-dT and mix of nucleotides at 42 
0C for 60 min. using a DNA Thermal Cycler 480 (Perkin Elmer Inc., Waltham, MA). 
Initial mRNA solutions contained  5µg of RNA per 100 µl.  
 Quantitative Real-Time PCR reaction (qPCR) was performed by FastStart 
SYBR Green Master (Roche) in a Light Cycler ® 96 (Roche) thermal cycler  for 40  
rounds. Beta-2-microglobulin (B2m) was chosen as a standard internal reference 
gene. Primer sequences; B2m: Forward: 5’–CGAGACCGATGTATATGCTTGC–3’, 
Reverse: 5’–GTCCAGATGATTCAGAGCTCCA-3’. cDNA was amplified using the 
TaqMan Gene Expression Assay Spexin (Rn01749065_m1, Applied Biosystems) 
and TaqMan Gene Expression Master mix (4369016, Applied Biosystems). Optimal 
hybridization temperature was established according to a gradient PCR and was 50 




Brain slices were dehydrated and embedded in paraffin,  sectioned on a microtome 
(Leica Microsystems, Germany) in the coronal plane (−2.00 to−2.80 mm from 
bregma) at 7 μm thickness, according to Paxinos & Watson’s The Rat Brain in 
Stereotaxic Coordinates (2007). After rehydratation, antigen retrieval (in a low pH 
antigen unmasking solution, Vector Laboratories) and blockage with 10% serum, 
brain sections were incubated overnight in 4 °C with a rabbit antibody against rat 
spexin (1:500, Phoenix Pharmaceuticals). Incubation with primary antibodies was 
followed by administration of biotynylated anti-rabbit secondary antibodies (1:200) for 
30min, and then an avidin-biotin-horseradish peroxidase complex (Vectastain ABC 
kit, Vector Labs) for another 30 min. Finally, 3,3′-diaminobenzidine (DAB) was used 
(Vectastain ABC kit, Vector Laboratories) for visualization of cells expressing 
particular neuropeptides. Sections (on the same slide) incubated with rabbit IgG 
instead of primary antibody were used as negative controls. Morphological analysis 
was performed with the use of Nikon Coolpix optic systems. Immunopositive cells 
were counted from three brain regions including hypothalamic arcuate, ventromedial, 
paraventricular and lateral nuclei, hippocampal CA1-CA3 areas with dentate gyrus 






Statistical analyses were performed using Statistica (Systat Software). Data 
are presented as mean ± SEM. Mean differences between experimental groups 
were analyzed using one-way ANOVA followed by Tukey’s post-hoc test. Differences 
were considered statistically significant at p ≤ 0.01 (asterisks). 
 
Results and Discussion 
 
Recent reports suggest a multidirectional pattern of SPX action in the brain. 
The potential involvement of this novel neuropeptide in various autonomic 
processes, including the regulation food intake, blood pressure, renal function and 
hormone release, has also come into consideration [5]. Nevertheless, SPX 
physiology is still extremely poorly investigated, to date less than 20 research articles 
dealing with this regulatory factor have been published. There is also no literature 
concerning the potential relationships between SPX signaling and drug 
administration.  
In this study we report for the first time that SPX mRNA and protein 
expressions are strongly downregulated in the hypothalamus after chronic 
escitalopram administration (45.13% and 23.06% of control respectively, p = 
0.00018).  A recent finding suggested that some SPX hypothalamic neurons take 
part in the central inhibition of food intake and energy homeostasis and the 
neuropeptide seems to be a potent anorexigenic factor in rats  [9]. Furthermore, a 
previous microarray study reported that the SPX gene was distinctly depressed in 
adipose tissue of obese humans, and it is postulated that SPX is an adipokine, which 
would potentially impact food intake, energy expenditure as well as long chain fatty 
acid (LCFA) turnover [10].  Interestingly, a decreased serum SPX concentration was 
recently revealed in obese children compared with normal-weight controls without 
any correlation with adipokines and insulin levels [24]. Taking into account that  
escitalopram causes weight gain [25, 26], one can hypothesize cautiously that its 
action may be related to the inhibition of SPX expression in the hypothalamus. It 
should not be completely excluded that a decrease in SPX signalling may be an 
alternative unknown mechanism of SSRI-dependent weight-gain. However, this 
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suggestion is not yet justified by our results and it has to be verified by further 
studies including behavioural tests. Giving the potent affinity of SPX to GALR2/3 
receptors [13] and suggested anorexigenic properties of galanin-like peptides 
(GALP) in mice [27, 28] but not in rats [28, 29] the potential changes in the 
hypothalamic GALRs expression after escilalopram administration requires further 
studies. They may be especially interesting in the context of suggestions that in 
mammals galanin affects food intake through GALR1 rather than GALR2/3 [13].  
On the other hand, escitalopram has the ability to diminish the activation of 
hypothalamic neurons containing melanin concentrating hormone (MCH) and to 
suppress REM sleep rebound [30]. The potential interplay between SPX and MCH 
signalling is so far unknown, however it is worth noting that escitalopram  may inhibit 
the action of another regulatory neuropeptide in the hypothalamus. Interestingly, a 
recent study reports that long-term treatment with escitalopram  increased the serum 
level of other orexigenic factor; neuropeptide Y (NPY) in the patients with depression 
[31]. 
Conversely, the neuropeptide gene expression level was increased in the 
hippocampus and striatum  (262.91%, and 280.79% of control respectively p = 
0.00017 and 0.0091). However, the number of SPX-expressing cells was 
significantly elevated only in the hippocampus, especially among the dentate 
granular neurons (540% of control). The increased number of SPX- immunopositive 
cells in the striatum was not statistically significant. These results are currently 
extremely difficult to interpret without molecular analysis of the potential relationship 
between SPX signalling and serotoninergic inputs in the studied brain regions. 
Perhaps, serotonin excess may promote the expression of the SPX gene in the 
hippocampus, thus escitalopram could increase the activity of SPX signalling in this 
structure through SERT inhibition.   
Our results partly correlate to data suggesting that escitalopram treatment  
induced changes in various rat hippocampal proteins (not neuropeptides), except for 
those involved in energy expenditure and neuroprotection [32] but it had no effect on 
hippocampal volume [33]. Interestingly administration of escitalopram during 
adolescence could modify the alterations of increased choline-containing compounds 
and decreased glutamate, N-acetylaspartate and myoinositol relative to the stable 
neurometabolite creatine in rat hippocampus [33]. Probably, escitalopram modulates 
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some cellular populations during neuronal differentiation in the rat dentate gyrus and 
the behavioural changes in these animals may be the consequence of an 
escitalopram mediated increase in specific subtypes of immature neurons [34]. 
The antipsychotic potential of the combined treatment of escitalopram, in 
therapeutic relevant doses, and the 5-HT1A receptor antagonist, WAY-100635, has 
been evaluated by assessment of conditioned avoidance (CAR) behaviour and the 
use of microdialysis in freely moving rats. The combined treatment was found to 
decrease both conditioned avoidance (CAR) behavior, without affecting the basal 
extracellular levels of dopamine in the nucleus accumbens (NAc) or in the striatum, 
suggesting an antipsychotic-like effect with mesolimbic selectivity. Furthermore, 
escitalopram, in combination with the partial 5-HT1A agonist, (-)-pindolol, decreased 
basal dopamine levels in the NAc [35].  
Despite its novelty, there are several limitations of the current study, which 
has to be taken into account. Firstly, there was rather small group of animals (only 4 
individuals) examined. No behavioural tests were performed, thus, while literature 
data support the use of escitalopram in the given dose, its antidepressant effects 
were unfortunately not validated. It should be emphasized that in the case of these 
medications, different classes may differently influence neuropeptide expressions, 
like in the case of fluoxetine [36] and venlafaxine on the galanin system [37]. The 
current study has not examined different time points. Antidepressant actions are 
chronically not necessarily related to the serotonergic system, other theories 
suggesting a role of diverse factors including neurotrophins have also been 
proposed [38] and serotonergic markers may remain unaltered after SSRI drugs at 
therapeutically relevant time points [39]. Thus, whether spexin expression is directly 
related to antidepressant actions or is a secondary consequence, has to be 
investigated in the future.  
At present, as antidepressant-related changes in peptide expression are not 
yet clarified, comparing the actions of escitalopram on SPX mRNA expression, in the 
defined brain structures, to its effects on other neuropeptides is unfortunately merely 
speculative. Although satisfactory explanation of spexin functions requires numerous 
further studies, even at this early explorative stage, SPX can be considered a 






  We have demonstrated for the first time, that extended treatment with an 
SSRI drug, modulates the expression of SPX mRNA in the rat brain. This suggests a 
so far unknown relationship between this novel regulatory factor and brain function, 
which has implications for food intake control, HPA axis modulation and probably 
additional brain functions. 
 
This work was partly based on the results of a research task carried out within 
the scope of the third stage of the National Programme ‘‘Improvement of safety and 
working conditions’’ partly supported in 2014–2016 – within the scope of research 
and development – by the Ministry of Science and Higher Education/ National Centre 
for Research and Development. The Central Institute for Labour Protection – 
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Fig. 1.  Quantitative PCR results of relative spexin mRNA expression levels in 
the rat hypothalamus, hippocampus and striatum. (A). Obtained results were 
normalized to beta-2-microglobulin reference gene. The number of spexin 
immunopositive cells in the examined brain structures (B). Data are presented as 
multiples/decimals of control (1) ± SEM. Differences were considered statistically 
significant at p ≤ 0.01 (asterisks). 
 
Fig 2. Representative expression of spexin in the rat hypothalamus, hippocampus 
and striatum in controls and after long-term treatment with escitalopram. Scale bars: 
50 m.  
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